［1］Martinez-Lopez A，Almazan-Fernandez FM，Perez-Lopez I，et al.Successful treatment of cutaneous metastatic melanoma with high-dose intralesional interleukin-2 treatment combined with cryosurgery［J］，Dermatol Ther，2018(15)：1-3.
［2］Gubin MM，Zhang X，Schuster H，et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens［J］.Nature，2014，515(7528)：577-581.
［3］Yadav M，Jhunjhunwala S，Phung QT，et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing［J］.Nature，2014，515(7528)：572-576.
［4］Larbcharoensub N，Mahaprom K，Jiarpinitnun C，et al.Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in ePstein-Barr virus-associated nasopharyngeal carcinoma［J］.American Journal of Clinical Oncology，2018，41(12)：1204-1210.
［5］Linnemann C，van Buuren MM，Bies L，et al.High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma［J］.Nature Medicine，2015，21(1)：81-85.
［6］Palodhi A，Ghosh S，Biswas NK，et al.Profiling of genomic alterations of mitochondrial DNA in gingivobuccal oral squamous cell carcinoma：Implications for disease progress［J］.Mitochondrion，2018，24(6)：1-27.
［7］Hundal J，Kiwala S，Feng YY，et al.Accounting for proximal variants improves neoantigen prediction［J］.Nature Genet，2018，2(3)：771-779.
［8］Mirjana E，Francesca F，Dietmar R，et al.Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy［J］.Frontiers in Immunology，2017，8(1)：1679-1687.
［9］Abedalthagafi M.Constitutional mismatch repair-deficiency：current problems and emerging therapeutic strategies［J］.Oncotarget，2018，9(83)：106-119.
［10］Wu J，Zhao W，Zhou B，et al.TSNAdb：A database for tumor-specific neoantigens from immunogenomics data analysis［J］.Genomics，Proteomics & Bioinformatics，2018,16(4)：21-30.
［11］Koalolu-Yalｉn Z，Lanka M，Frentzen A，et al.Predicting T cell recognition of MHC class I restricted neoepitopes［J］.Oncoimmunology，2018，7(11)：201-238.
［12］Blaha DT，Anderson SD，Yoakum DM，et al.High-throughput stability screening of neoantigen/HLA complexes improves immunogenicity predictions［J］.Cancer Immunol Res，2018，15(3)：12-41.
［13］Kinkead HL，Hopkins A，Lutz E，et al.Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer［J］.JCI Insight，2018，3(20)：e1-e15.
［14］Duan F，Duitama J，Al Seesi S，et al.Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity［J］.J Exp Med，2014，211(11)：2231-2248.
［15］Marty R，Thompson WK，Salem RM，et al.Evolutionary pressure against MHC class Ⅱ binding cancer mutations［J］.Cell，2018，175(2)：416-428.
［16］Fridman WH.From cancer immune surveillance to cancer immunoediting：Birth of modern immuno-oncology［J］.J Immunol，2018，201(3)：825-826.
［17］Aragon-Sanabria V，Kim GB，Dong C，et al.From cancer immunoediting to new strategies in cancer immunotherapy：The roles of immune cells and mechanics in oncology［J］.Adv Exp Med Biol，2018(092)：113-138.
［18］Martin SD，Wick DA，Nielsen JS，et al.A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer［J］.Oncoimmunology，2018，7(1).doi:10.1080/2162402X.2017.1371895.
［19］O' Donnell JS，Teng MWL，Smyth MJ，et al.Cancer immunoediting and resistance to T cell-based immunotherapy［J］.Nat Rev Clin Oncol，2018，5(21)：e1-e17.
［20］Efremova M，Rieder D，Klepsch V，et al.Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution［J］.Nature Communications，2018，9(1)：32-45.
［21］MS Rooney，SA Shukla，CJ Wu，et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity［J］.Cell，2015，160(1-2)：48-61.
［22］Deniger DC，Pasetto A，Tran E，et al.Stable，non-viral expression of mutated tumor neoantigen-specific T-cell receptors using the Sleeping Beauty transposon/transposase system［J］.Molecular Therapy，2016，24(6)：1078-1089.
［23］Li L，Goedegebuure SP，Gillanders WE.Preclinical and clinical development of neoantigen vaccines［J］.Annals of Oncology，2017，28(suppl_12)：xii11-xii17.
［24］Yi M，Qin S，Zhao W，et al.The role of neoantigen in immune checkpoint blockade therapy［J］.Exp Hematol Oncol，2018，7(1)：28-39.
［25］Ott PA，Hu Z，Keskin DB，et al.An immunogenic personal neoantigen vaccine for patients with melanoma［J］.Nature，2017，547(7662)：217.
［26］Sahin U，Derhovanessian E，Miller M，et al.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer［J］.Nature，2017，547(7662)：222-226.
［27］Lu YC，Zheng Z，Robbins PF，et al.An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors［J］.Molecular Therapy，2018，26(2)：379-389.
［28］Terhi K，Johanna O.The potential of donor T-cell repertoires in neoantigen-targeted cancer immunotherapy［J］.Frontiers in Immunology，2017(8)：1718-1742.
［29］Wilson EA，Anderson KS.Lost in the crowd：identifying targetable MHC class I neoepitopes for cancer immunotherapy［J］.Expert Rev Proteomics，2018，15(12)：1065-1077.
［30］Strnen E，Toebes M，Kelderman S，et al.Targeting of cancer neoantigens with donor-derived T cell receptor repertoires［J］.Science，2016，352(6291)：1337-1341.
［31］Wirth TC，Kühnel F.Neoantigen targeting-dawn of a new era in cancer immunotherapy［J］.Frontiers in Immunology，2017(8)：1848.